Novel specific human and mouse stromelysin-1 (MMP-3) and stromelysin-2 (MMP-10) antibodies for biochemical and immunohistochemical analyses by Mirastschijski, Ursula et al.
 Novel specific human and mouse stromelysin-1 (MMP-3) and stromelysin-2 (MMP-10) antibodies 
for biochemical and immunohistochemical analyses 
 
Ursula Mirastschijski, MD, PhD1, Nilima Dinesh*,1 Sudarson Baskaran*,1 Dirk Wedekind,PhD2 Jelena 
Gavrilovic, PhD3 Megan Y. Murray, PhD3 Damon Bevan, PhD3 Sørge Kelm, PhD1  
 
1 Wound Repair Unit, Centre for Biomolecular Interactions Bremen, University of Bremen, Bremen, 
2Institute for Laboratory Animal Science, Hannover Medical School, Hannover, Germany; 3School of 
Biological Sciences, University of East Anglia, Norwich, UK  
 
*Both authors contributed equally to this work. 
 
 
 
Corresponding author: 
Prof. Dr. Dr. Ursula Mirastschijski 
CBIB, FB2 
University of Bremen 
Leobener Str/NW2 
28359 Bremen 
Tel: +49 421 218 63224 
Fax: +49 421 218 63228 
Email: mirastsc@uni-bremen.de 
 
Key words: stromelysin 1 - MMP-3, stromelysin 2 - MMP-10, peptide antibodies, cross-reactivity 
This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/wrr.12704 
 
This article is protected by copyright. All rights reserved.
 Short running title: Novel specific MMP-3 and MMP-10 antibodies 
  
 
 
This article is protected by copyright. All rights reserved.
 Abstract 
 
Matrix metalloproteinases (MMP) are a family of more than 25 zinc-dependent enzymes that are centrally 
involved in cellular migration, tissue remodelling, cancer invasion and metastasis. Besides degrading 
extracellular matrix proteins, MMPs are crucial for growth factor and cytokine release and activation. At 
the same time, they can inactivate inflammatory mediators and enzymes themselves through protein 
degradation. Subclasses of MMPs include collagenases, gelatinases, stromelysins, membrane-bound 
MMPs and others. With regard to the stromelysin subfamily, 3 members exist, e.g. stromelysin-1 (MMP-
3), stromelysin-2 (MMP-10) and stromelysin-3 (MMP-11). MMP-3 and MMP-10 share extensive 
similarities at the amino acid level that made it difficult to develop specific antibodies distinguishing 
between MMP-3 and MMP-10. Scrutinizing published data on and performing different analyses with 
detection of both stromelysins with commercially available or lab-made antibodies showed ambiguous 
results with regard to specificity of antibodies used to date. We developed new specific antibodies against 
the most divergent parts of the active forms of both proteins. We assessed the specificity of our novel 
specific anti-human and anti-mouse MMP-3 and MMP-10 antibodies in cell lysates and different human 
and murine skin tissues. Tests analysing specificity of the novel antibodies included Western 
immunoblotting, immunofluorescence and immunohistochemistry on paraffin sections. Analyses 
demonstrated specific detection of respective protein for human or mouse samples except for the anti-
human MMP-3 antibody. The aim of this summary was to call attention the MMP research community to 
distinguish clearly between both enzymes. Our new specific anti-mouse MMP-3 and both MMP-10 
antibodies allow us to address this detection problem and to enable comparative studies between both 
stromelysins with regard to their respective location and function in the tissue. 
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 Introduction 
Since the discovery of the first matrix metalloproteinase (MMP), i.e. collagenase by Gross and Lapière in 
19621 numerous other MMPs have been described. Meanwhile, this family of zinc-dependent 
endopeptidases has grown up to 25 currently known extracellular members.2 Subgroups of the MMP 
family constitute the collagenases (MMP-1, MMP-8, MMP-13), gelatinases (MMP-2, MMP-9), 
stromelysins (MMP-3, MMP-10, MMP-11) and membrane-bound MMPs. 
Stromelysin-1 (MMP-3) was first purified from bone tissue and called proteoglycanase in 1983.3 Due to its 
stromal origin and hydrolytic activity, it was named stromelysin in 1985.4 Okada isolated two isoforms of 
the enzyme and named it MMP-3 in order to distinguish it from MMP-1 and MMP-2.5 MMP-3 is secreted 
as a 57 kDa proenzyme and activated by cleavage of the propeptide resulting in a 45 kDa peptide. By 
autolytic cleavage, active MMP-3 is further processed to a 28 kDa form with indistinguishable activity and 
substrate specificity.6 Substrates for MMP-3 are many extracellular matrix proteins (e.g. collagen type II 
and III, laminin, proteoglycans), cell surface proteins (e.g. E-cadherin) and other MMPs (MMP-1, MMP-8 
and MMP-13) that it activates by pro-peptide cleavage. Furthermore, it is a potent activator of 
plasminogen by binding to tPA (tissue-type plasminogen activator).6 MMP-3 enzyme expression is 
induced by cytokines and tumour necrosis factor-alpha (TNF-α) in synovial fibroblasts4 and skin.7 During 
skin wound healing, keratinocytes at the wound margin express MMP-3.8 MMP-3 knock-out mice develop 
normally and show no specific phenotype. Challenged by wounding, cutaneous healing is marked by 
reduced wound contraction albeit uncompromised epithelial migration.9 MMP-3 overexpression in 
cutaneous keratinocytes facilitates wound healing by accelerated wound closure (unpublished own data). 
Besides skin repair, MMP-3 plays an important physiological role in various organs, e.g. mammary gland, 
cartilage, alveolar wound healing and some tumours. Main interest focussed on MMP-3 has been due to 
its contribution in pathological conditions such as osteoarthritis, synovitis, cartilage destruction and 
promotion of metastasis by E-cadherin cleavage.6  
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An important problem in the interpretation of immunological data for MMP-3, e.g. derived from Western 
blots or immunohistochemistry, has been the fact that MMP-3 is extremely similar to stromelysin 2 (MMP-
10). MMP-10 is secreted as 54 kDa protein in its latent form being subsequently activated to a 44 kDa 
protease, just like MMP-3. It was cloned and described for the first time by rat stromelysin cDNA 
hybridisation based on the high similarity in their mRNA sequences.10 A comparison between MMP-3 and 
MMP-10 revealed that both enzymes are extremely similar and share up to 78% identity at the amino acid 
level in their active forms. Differences exist with regard to pH optimum,11 enzyme activation and 
expression in various cells.8 MMP-10 shares several features with MMP-3, namely the ability to cleave 
many extracellular matrix proteins,12 e.g. proteoglycans13 and to activate collagenases.14 Further 
substrates are collagen type III and IV, fibronectin and aggrecan.15 
 
Whilst much research has focused on the specific biological functions of MMP-3 or MMP-10, only a few 
groups have addressed the problem of developing specific immunodetection based tools to clearly 
distinguish between both enzymes.8, 16-18 Although some of the strategies to make specific antibodies or 
block residual cross reactivity seem convincing, there is little published proof for the specificity of the used 
antibodies for direct comparison between MMP-3 and MMP-10. Due to almost identical protein migration 
behaviour in SDS PAGE, Western blot detection does not provide direct evidence for identification of the 
protein bands. It is even more problematic, if only immunohistology is applied without further biochemical 
identification of the antigen. Hence, we want to alert researchers to the difficulty but necessity to clearly 
distinguish between MMP-3 and MMP-10, and to point out that insufficiently characterised antibodies 
should be dealt with great care, especially as one may compensate for the absence of the other, for 
example in knockout animals. To overcome specificity issues with several commercially available 
antibodies tested, we developed new antibodies against both enzymes in mouse and in humans and 
verified their specificity by direct comparison between MMP-3 and MMP-10. 
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Methods 
First, commercially available MMP-3 and MMP-10 antibodies were used for Western Immunoblotting. 
Because of cross-reactivity of antibodies between both enzymes, novel peptides were designed as tailor-
made antigens to generate novel antibodies selective for either MMP-3 or MMP-10. The “Method” section 
is divided into a) methods that describe the analyses with the commercially available antibodies, then b) 
the design to develop novel antibodies and finally, c) the methods for testing all novel antibodies. 
 
a) Methods for analyses with commercially available antibodies 
 
Skin tissue provenience and ethics 
Patients undergoing plastic surgery for reduction plasty or wound excision donated skin after giving their 
written consent. The Ethics Committee of the Medical Chamber of Bremen (No. 336/12 and RA/RE-336) 
approved the study. The skin was kept at 4°C in 0.9% NaCl (saline) and used within 4 hours after 
removal.  
 
Animals, husbandry and ethics 
MMP-3 and wildtype animals 
All animals were kept in in cages with a ground area of 440 cm2 under controlled standardised conditions: 
temperature 21 ± 2°C, relative humidity 50 ± 5%, and artificial light (14 h light, 10h dark, light on at 06:00 
a.m.). Sterilised commercial softwood granulate bedding was used (Lignocel, Altromin; Lage, Germany). 
Autoclaved commercial pellet diet (Altromin 1314) and autoclaved water were provided ad libitum.  
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 Whenever possible, mice were kept in sibling groups. The microbiological status was examined as 
recommended by FELASA and absence of listed microorganisms, except Pasteurella pneumotropica, 
Helicobacter sp., and Norovirus was confirmed. 
The experiments were in accordance with the German Animal Welfare Legislation and approved by the 
local Institutional Animal Care and Research Advisory Committee and permitted by the Lower Saxony 
State Office for Consumer Protection and Food Safety (reference number 42500/1H, 13A404 and 522-27-
11/02-00/118). 
Mice of the colony Stock Mmp3tm1Mol, kindly provided by GA Rosenberg, Albuquerque, NM, USA were 
delivered on a non-standardized genetic background. After SNP marker assisted backcrossing to 
C57BL10.RIIIH2r (N7) C57BL10.RIIIH2r-Mmp3tm1Mol /Ztm mice were maintained as congenic inbred strain. 
Informative SNPs were rs13459107, rs13459122, rs13459145, rs13459160, rs13475760, rs13475913, 
rs13476182, rs13476801, rs13476956, rs13477019, rs13477132, rs13477622, rs13477746, rs13477824, 
rs13477863, rs13478000, rs13478995, rs13479233, rs13479522, rs13479733, rs13479929, rs13479999, 
rs13480014, rs13480122, rs13480362, rs13480759, rs13480829, rs13480835, rs13481014, rs13481039, 
rs13481117, rs13481439, rs13481573, rs13481634, rs13481676, rs13482397, rs13482551, rs13482990, 
rs13483208, rs13483296, rs13483369, rs13483883, rs29359333, rs31233932, rs3687811, rs3711383, 
rs4165065, rs4225661, rs6371316. Genotype of the Mmp3 locus was controlled by PCR using 
oligonucleotides MMP3-null neo cassette sense: 5`- CGG ATT TGC CAA GAC AGA GTG – 3` and 
MMP3-null neo cassette antisense: 5`- GGC TAC CCG TGA TAT TGC TGA A – 3`. Genetic background 
of the inbred mice was regularly controlled.19 The strain C57BL10.RIIIH2r-Mmp3tm1Mol /Ztm is abbreviated 
as BL10. 
MMP-3 deficient mice were crossed back to a homozygous BL10 background for 10 generations as 
described above. Male MMP-3 knock-out and BL10 wildtype mice were used for this experimental setting. 
Full-thickness, excisional wounds in MMP-3 knock-out and BL10 wildtype mice were made as described 
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 elsewhere.20 Mice were sacrificed by decapitation four or eight days after wounding. The skin was 
excised and kept in cold PBS buffer for immediate use.  
 
Experimental model setting for MMP-10 experiments 
Full-thickness excisional wounds in non-diabetic C57BL/KsOlaHsd-Db/+ mice (henceforth referred to as 
Db+ mice; Harlan UK Ltd) were made essentially as described previously21 under Project Licence no. 
PPL80/1799. For the study reported here, two wounds were made in the dorsal surface of Db+ mice, 
which were killed under Schedule 1 of the 1986 Animal Scientific Procedures Act (UK) 7 days post-
wounding. Non-wounded skin was excised at 2 cm distance from the wound site. Skin tissue was cut into 
small explants and cultured for 24 hours in DMEM, (supplemented with mM L-glutamine, 100 units/ml 
Penicillin/Streptomycin and 10% foetal calf serum). Monensin interferes with protein glycosylation in the 
Golgi apparatus and extracellular secretion.22 To prevent MMP secretion from cells/explants, Monensin 
(2µM) was added to samples of MMP-10 experiments for the final 3h of culture.23 At the end of the culture 
period tissue was snap frozen in liquid nitrogen.  
 
Western Immunoblotting using commercially available antibodies  
Human or mouse skin was homogenized in a modified RIPA lysis buffer (0.1M Tris/HCl, 0.15M NaCl, 1% 
Triton X-100, 0.1% SDS, pH 7.4) containing complete protease inhibitor cocktail without EDTA (Roche, 
Mannheim, Germany). Protein content was quantified using the BCA method (Pierce, Rockford, IL, USA). 
To analyse skin wound extracts by Western blot, 10μg of protein were separated in a 12.5% SDS-PAGE 
gel and transferred into a PVDF membrane. Proteins were analysed by using different commercially 
available MMP-3 or MMP-10 antibodies available (Suppl Table 1) and lab-made antibodies (Suppl Table 
2).24 Donkey antibodies to rabbit, goat, rat, and sheep (all from Dianova, Hamburg, Germany) were used 
as secondary antibodies. The reaction was developed by using ECL Prime Western Blotting Detection kit 
from Amersham (GE Healthcare, UK). 
 
 
This article is protected by copyright. All rights reserved.
 For MMP-10 detection in Db+ mouse skin, snap frozen tissue was minced finely with scissors in the 
extraction buffer (10mM Tris-HCL ph7.6, 10mM NaCl, 3mM MgCl2, 1% NP-40 and protease inhibitors) 
prior to full disruption in the TissueLyser II (Qiagen). Following protein estimation (BCA assay; Pierce) 
proteins (1.9µg/track) were loaded onto 10% SDS-PAGE gels and transfer to PVDF membrane and 
Western blotting was performed as described above. Recombinant human MMP10 (kind gift from 
Professor Andrew Rowan, University of Newcastle) served as a positive control. 
 
b) Development of novel antibodies 
 
RNA isolation and cDNA preparation 
Total RNA was isolated by homogenization of the human keratinocyte cell line HaCat, according to 
manufacturer’s protocol (peqGOLD TriFast kit, PEQLAB, Erlangen, Germany) and as described 
elsewhere25 using 1 mL TriFast for every 50-100 mg of cell material. cDNA synthesis was carried out 
according to manufactures protocol (RevertAid™ First Strand cDNA Synthesis Kit, Thermo Scientific, 
Schwerte, Germany). 
 
PCR and Production of recombinant proteins  
Hu/m MMP-3 and MMP-10 were amplified and plasmids were constructed using standard recombinant 
cloning techniques and integrity of amplification products were verified by DNA sequencing. MMPs were 
amplified from cDNAs derived from primary mouse keratinocytes or from the human keratinocyte cell line 
HaCat using the following primers:  
Nested sense mMMP-3 5´ GTGGTACAGAGCTGTGGGAAG 
sense mMMP-3 5´ CGGGATCCATGAAAATGAAGGGTCTTCCG 
Nested anti-sense mMMP-3 5´ CTCAGGATGCCTTCCTTG 
Anti-sense mMMP-3 5´ CGGAATTCACAATTAAACCAGCTATTGCT 
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 Nested sense huMMP-3 5´ CAACATAGAGCTAAGTAAAGCC 
sense huMMP-3 5´ CGGGATCCATGAAGAGTCTTCCAATCCTACTG 
Nested anti-sense huMMP-3 5´ GCCCATATTGTGCCTTCTAC 
Anti-sense huMMP-3 5´ CGGAATTCACAATTAAGCCAGCTGTTACT 
Nested sense mMMP-10 5´ CCAGGTGCTAGAGAAGGATCG 
sense mMMP-10 5´ CGAGATCTATGGAGCCACTAGCCATCCTG 
Nested anti-sense mMMP-10 5´ TACAGGGTTGTATATGTCTTG 
Anti-sense mMMP-10 5´ CGGAATTCGCACAGCAGCCAGCTGTT 
Nested sense huMMP-10 5´ GTAAGGGCAGTGAGAATG 
sense huMMP-10 5´ CGGGATCCATGATGCATCTTGCATTCCTTGTG 
Nested anti-sense huMMP-10 5´ ACACCCATATCTGTCTTCCCC 
Anti-sense huMMP-10 5´ CGGAATTCGCAATGTAACCAGCTGTTACT 
containing BamHI and EcoRI (m/hu MMP-3 and hu MMP-1) and BglII and EcoRI (m MMP-10) restriction 
sites. Amplification products were cloned in frame with the StrepTag coding sequence into BamHI/EcoRI 
digested pcDNA3 Amp StrepTag vector as described previously.26 
 
Novel peptide MMP-3 and MMP-10 antibodies 
Specific peptide antibodies raised against human and mouse MMP-3 and MMP-10 were purchased from 
Biomatik (Cambridge, Canada - SA0033 peptide polyclonal antibody package) using specific peptides for 
mMMP-3 (CASPDVLVVPTKSNSLEPETSP – peptide1 and CAEDFPGVDSRVDAVFEA – peptide 2), 
huMMP-3 (CDSPETPLVPTEPVPPEPGTPA – peptide 1 and CAEDFPGIDSKIDAVFEE – peptide 2), 
mMMP-10 (CSSDATVVPVLSVSPRPETPD – peptide 1 and CTDDFPGIEPQVDAVLHE – peptide 2) and 
huMMP-10 (CASTEEPLVPTKSVPSGSEMPA – peptide 1 and CADDFPGVEPKVDAVLQA – peptide 2) 
for immunization of rabbits for each peptide using the manufacturer`s service. The anti-sera were affinity 
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 purified against the respective isoform specific peptide used for immunization and the titre was 
determined by ELISA by the manufacturer. 
 
c) Analyses for comparison between commercial and designed antibodies 
 
Cell culture and transfection 
HepG2 and COS-7 were grown in DMEM supplemented with 10% fetal bovine serum (FBS), 100 U x mL-1 
penicillin and 50 µg x mL-1 streptomycin at 37°C in a humidified atmosphere of 5% (vol ⁄ vol) CO2. 
Transient transfection with plasmids encoding C-terminally Strep-tagged hu/m MMP-3 and MMP-10, 
respectively was carried out as described elsewhere.25 For protein expression, HepG2 and COS-7 cells 
were transfected with the indicated amount of the different plasmids and were harvested after 24 h.25  
 
Western blot analysis 
HepG2 cells were lysed 24 h post-transfection using TNE buffer (50mM Tris, 140mM NaCl, 5mM EDTA 
adjusted to pH 7.5). Wound tissues were homogenized in RIPA buffer as described above 27 at pH 7.4. 
Homogenates were then centrifuged at 12,000g for 10 min and supernatants of the homogenized tissues 
collected and stored at -20°C until further analysis. Aliquots of the cell lysates or tissue extracts were 
loaded on 10% SDS Polyacrylamide gel and electrotransferred onto PVDF membranes. The membranes 
were incubated for 1 hour in a blocking buffer (20mM Tris-HCl buffered saline containing 3% nonfat milk 
powder and 0.1% Tween 20). Blots were incubated overnight either with our peptide specific antibodies 
against (human and mouse) MMP-3 and MMP-10 (Biomatik; 1:200) or commercial antibodies as follows: 
anti-MMP-3 antibody from Acris Antibodies GmbH (AP22793PU-N) (1:125), Assay Biotech (CO272) 
(1:500), MBL international (JM3523) (1:200), Novus Biologicals (NB100-91878) (1:500), Novus 
Biologicals (EP118Y) (1:500) (Suppl Table 1) and D248/6 sheep-anti human MMP-10 17 (Suppl Table 2). 
After additional washes, the blots were incubated with the corresponding secondary antibody conjugated 
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 with peroxidase detected by addition of chemiluminescent substrate according to the kit used 
(ThermoScientific ECL Western blot detection kit).  
 
Immunofluorescence 
For the immunofluorescence analysis of C-terminally Strep-tagged human and mouse MMP-3 and MMP-
10 in transfected cells, COS-7 cells (3 x 104) were plated on coverslips in a 24 well plate and were grown 
overnight to reach 80% confluence. Fixation and permeabilisation of cells were performed as described 
previously.25 COS-7 cells were immunostained using the same antibodies already used for Western blot 
analysis. After washing twice with PBS/2% BSA, cells were treated for 90 min in PBS/2% BSA at room 
temperature in the dark with donkey anti-rabbit antibody Cy3 or donkey anti-mouse antibody Cy5 
conjugate (Dianova, Hamburg, Germany). Cells were washed twice with PBS, embedded in Fluoro-Gel II 
(EMS, Hatfield, USA) and images were captured with an Apotome fluorescence imager (ApoTome, Axio 
Imager Z1, Zeiss, Jena, Germany). Commercial and lab-made antibodies were used as stated in Suppl 
Tables 1 and 2. All antibodies were used at a concentration of 1:200. After washing again with PBS 
containing 2% BSA, the cells were incubated with the corresponding secondary antibody conjugated with 
Cy3 or Cy5 fluorophore.  
 
Immunohistochemistry 
Tissues were fixed in 4% paraformaldehyde for 12 hours, dehydrated and embedded in paraffin. Four µm 
sections were stained using antibodies listed in Suppl Table 1. Immunostaining was performed by the 
avidin-biotin-peroxidase complex technique (DC137C100 Kit; DCS Innovative Diagnostic Systems, 
Hamburg, Germany). Diaminobenzidine was used as a chromogenic substrate and hemalaun was used 
as the counterstain, which were described in detail.28 Imaging was performed with the Nikon Eclipse Ti 
microscope and digitized pictures analysed using Nis-Elements BR 3.2™ software (Nikon). 
Immunohistochemical stainings with peptide antibodies were performed on tissues from at least three 
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 different donors, e.g. wildtype animals (n=6), MMP-3 knock-out animals (n=4), human burned skin and 
human normal skin (each n=3). 
 
Sandwich Immunoassay for MMP detection 
For quantitative MMP-3 and MMP-10 analysis, two different sandwich immunoassays were purchased 
from Meso Scale Discovery®, Gaithersburg, MD, and tested for MMP-3 and MMP-10 cross-reactivity. The 
human MMP-2-Plex ultra-sensitive kit detecting human MMP-2 and MMP-10 (#KI15033C) and the human 
MMP-3-Plex ultra-sensitive kit detecting human MMP-1, MMP-3 and MMP-9 (#KI15034C) were used 
according to manufacturer’s instructions. Standard series of each kit were added to the plates and 
detection recorded. 
 
 
Results 
The need for novel MMP-3 and MMP-10 antibodies resulted from the disappointing attempt to 
demonstrate lack of MMP-3 protein in MMP-3 knock-out mice by Western blot analysis. Using different 
commercial antibodies, we still detected distinct bands with the same electrophoretic running behaviour in 
wildtype and in MMP-3 knock-out animals despite of negative results with DNA and RNA analysis (data 
not shown). We reasoned that the most likely explanation for this phenomenon was antibody cross-
reactivity due to the extreme similarity between MMP-3 and MMP-10 proteins6. 
 
Analyses with commercially available and lab-made antibodies  
To confirm our suspicion of unwanted cross-reactivity of anti-MMP-3 antibodies with MMP-10, we 
controlled the specificity of different commercial antibodies against recombinant MMP-3 and MMP-10 
derived from human or mouse origin by Western blot analysis (Fig. 1A). To ease comparative analyses, 
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 we ectopically overexpressed C-terminally Strep-tagged human and mouse MMP-3 or MMP-10 in HepG2 
cells and loaded aliquots of the cell lysates for SDS-PAGE and subsequent Western-blot analysis (Fig. 
1B). Interestingly, none of the commercial anti-MMP-3 antibodies that we used was able to clearly 
distinguish between MMP-3 and MMP-10 (Fig. 1).  
 
To verify specific binding of commercial antibodies in tissue sections, immunohistochemistry on murine 
skin from wildtype (BL10) or MMP-3 knock-out mice using commercial antibodies JM3523 and MAB 548 
was performed (Suppl Table 1, Fig. 2). Positive staining for MMP-3 was seen with MAB 548 in both MMP-
3 wildtype and MMP-3 deficient mouse skin (Fig. 2C,D) and unspecific staining in both groups with 
JM3523 (Fig. 2A+B). Next, immunofluorescence staining was performed on COS-7 cells overexpressing 
human or mouse MMP-3 or MMP-10 with commercial antibodies M3B (Novus Biologicals, #NB110 – 
57221) and M3C (Abcam, #EP1186Y) (Fig. 3). Good detection of human and mouse MMP-3 was noted 
with both, M3B and M3C (Fig. 3A,B). However, these antibodies showed cross-reactivity with human 
MMP-10 (Fig. 3C), but not with mouse MMP-10 (Fig. 3D).  
 
In the next step, we used lab-made antibodies for MMP-3 (L50/6) or MMP-10 (D248/6 or IW13, Suppl 
Table 2) for Western blot analysis (Fig. 4). As previously reported for human MMP-10,24 the sheep anti-
mouse MMP-3 (L50/6)24 showed weak cross-reactivity with mouse MMP-10 (Fig. 4A) and the sheep anti-
human MMP-10 antibody D248/6 17 detected additional bands as expected (Fig. 4B). Hence, the need for 
specific anti-mouse and anti-human MMP-3 antibodies that could clearly differentiate between both 
enzymes was obvious. The problem of cross-reactivity was hitherto only addressed by the research group 
around Gillian Murphy and co-workers.17, 23, 29, 30 Aside from the D248/6 sheep anti-human MMP-10 
antibody, another sheep antibody IW13 was generated and reported to be highly specific for MMP-10.31 
Detection of murine MMP-10 with the anti-human MMP-10 antibody IW13 is shown with Western blot in 
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 murine skin extracts (Fig. 4C). Additionally, IW13 detects MMP-10, but not MMP-3 in Western blot 
analysis (personal communication Professor Gillian Murphy, data not shown). 
 
Antibody development 
As stated above, screening commercially available antibodies against MMP-3 revealed inherent 
difficulties with regard to specificity (Fig. 1). Furthermore, cross-reactivity of these MMP-3 antibodies was 
insufficiently stated in most product sheets. It is still problematic to verify the antibody’s specificity due to 
the high protein sequence similarity between the active forms of MMP-3 and MMP-10 (Tab. 3) and 
because of scarce published data showing direct comparison between both enzymes in the same study. 
Therefore, our first attempt was to identify peptide regions with the highest degree of dissimilarities (Fig. 
5). Then, we used those regions for generating specific antibodies that are able to reliably distinguish 
between MMP-3 and MMP-10 with the goal to make species-specific (human or mouse specific) 
antibodies as well.  
 
Analyses and tests with our new antibodies against MMP-3 and MMP-10 
A series of new peptide specific affinity-purified antibodies (Biomatik, Canada) was raised against 
selected peptides of human and mouse MMP-3 or MMP-10 as described under Methods. With these 
antibodies the following enzyme and species specificities were observed by Western blot analysis of cell 
lysates (Tab. 4, Fig. 6). Anti-mouse MMP-3 peptide 1 showed high species and enzyme specificity (Fig. 
6A) whereas peptide 2 was unspecific. Anti-human MMP-3 peptide 1 detected the respective protein with 
species specificity, however, with strong cross-reactivity with a peptide migrating at around 40 kDa (Fig. 
6B). Attempts to identify this 40 KDa protein by immunoprecipitation and subsequent MALDI analysis 
were not successful (data not shown). The antibody raised against peptide 2 of human MMP-3 gave no 
specific signal using Western blot analysis (Fig. 6B). Anti-mouse MMP-10 peptide 1 and peptide 2 were 
highly specific for mouse MMP-10 (Fig. 6C). Anti-human MMP-10 peptide 1 and peptide 2 were specific 
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 for the protein but peptide 2 also recognised murine MMP-10 (Fig. 6D). As a consequence, peptide 1 
antibodies of all enzymes were used for further analysis. 
 
Next, the new peptide-derived anti-MMP-3 and anti-MMP-10 antibodies were tested by 
immunofluorescence on COS-7 cells ectopically expressing strep-tagged human or mouse MMP-3 or 
MMP-10, respectively (Fig. 7). The binding of antibodies against mouse MMP-3, mouse MMP-10 and 
human MMP-10 was selective for the cells expressing the respective antigens. The antibody raised 
against human MMP-3 bound to cells expressing any of the four proteins (Fig. 7). In parallel, stainings 
with an anti-strep antibody were performed to confirm protein expression. Images of anti-strep staining 
are shown in Suppl. Fig. 1.  
 
Immunohistochemistry (IHC) with peptide antibodies was performed on paraffin sections of human burn 
wounds and normal skin tissue (Fig. 8) and of murine excisional wounds (Fig. 9) in MMP-3 knock-out 
mice or wildtypes. As shown for fluorescence microscopy on MMP overexpressing cells, the anti-mouse 
MMP-3 antibody was also specific in tissue IHC (Fig 8A, 9A), no staining was observed in human tissue 
(Fig 8A). The anti-mouse MMP-3 antibody bound specifically to mouse MMP-3 (Fig. 9A) with strong 
staining of epidermal cells. MMP-3 specificity was further confirmed by immunohistochemistry in MMP-3 
knock-out mouse skin tissue, which was not stained (Fig. 9A). With regard to anti-mouse MMP-10 (Fig 
8B, 9B), mild cross-reactivity was found only in human burned but not in normal skin tissue (Fig. 8B). 
Strong immunopositivity was found in murine skin tissues with prominent nuclear staining for MMP-10 in 
both MMP-3 wild-type and MMP-3 knock-out murine skin cells (Fig. 9B). There was strong detection of 
MMP-3 by the anti-human MMP-3 antibody in burned skin and weak staining in the basal layer of 
epidermis and in the dermis of normal human skin (Fig. 8C). Distinct cross-reactivity was found with the 
human anti-MMP-3 antibody in murine tissue where it stained the whole epidermis in tissues of both 
murine strains (Fig. 9C) in contrast to the specific anti-mouse MMP-3 antibody that showed 
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 immunopositivity only in the upper epidermal layers of MMP-3 wildtype animals (Fig. 9A). The antigen 
recognition was unspecific because the epidermal layer of MMP-3 knock-out tissue was stained as well 
by the human anti-MMP-3 antibody. The human anti-MMP-10 antibody was specific for human tissue 
(Fig. 8D) with only mild background staining in mouse tissue (Fig. 9D). 
 
Sandwich Immunoassay 
Despite of the fact that the manufacturer stated cross-reactivity of MMP-3 and MMP-10 using the MSD® 
multi-spot assay system, only a high concentration of 25 ng/mL MMP-10 was detected as 103-fold lower 
MMP-3 concentration when added to the kit that detects human MMP-1, MMP-3 and MMP-9 (arrow, Fig. 
10C). No cross-reaction was detected when MMP-3 up to a concentration of 25 ng/mL was added to the 
kit that detects human MMP-2 and MMP-10 (Fig. 10E). Hence, this sandwich immunoassay seems to be 
reliable for differentiating between human MMP-3 and MMP-10 at concentrations in the range of 10 
pg/mL to 10 ng/mL. 
 
Literature overview for the use and verification of anti MMP-3 and MMP-10 antibodies 
 
We felt that it is important to demonstrate the chronology in the use and development of antibodies raised 
against MMP-3 and MMP-10 to get an overview concerning the difficulties in the interpretation of results 
of antibodies against MMP-3 and MMP-10 (Suppl Table 5). Clearly, a small number of groups working in 
this field made the effort to develop specific antibodies.24, 29, 31, 32 Unfortunately, a direct comparison of 
these antibodies with respect to their reactivity with MMP-3 and MMP-10 was not provided in any of these 
studies. Of note, MMP-10 was first discovered in 1988 and cloned by Muller et al.10 In the following years, 
lab-made antibodies were then described.8, 31, 33 At the time when Allan et al published their work,29 
stromelysin-2 protein was not yet available and recombinant or purified proteins from different species 
were not available for the analysis of inter-species cross-reactivity. Later, Hembry et al noticed a weak 
 
 
This article is protected by copyright. All rights reserved.
 cross-reactivity of the MMP-3 antibody with MMP-10.31 Interestingly, while they detected many positively 
stained cells with the MMP-3 antibody, no cells were positive with the MMP-10 antibody31 supporting the 
notion that this anti-MMP-10 antibody did not react with MMP-3. In the study of Dew et al 24 species and 
enzyme cross-reactivity of the anti-mouse MMP-3 antibody was described for human stromelysin-1 MMP-
3) and stromelysin-2 (MMP-10).24 Bord et al16 used the sheep anti-human MMP-329 and sheep anti-MMP-
1031 antibodies from the Murphy lab for immunostaining. The authors stated that the minimal cross-
reactivity of the MMP-3 antibody29 was blocked with the MMP-10 peptide used for the immunization 
without, but no direct comparison was shown.16 In support of their statement, Bord et al observed that 
different cells or regions were immunostained with either the MMP-3 or MMP-10 antibodies.16 Lees et al32 
made rabbit anti-MMP-3 antibodies but checked cross-reactivity solely against MMP-1, MMP-2 and MMP-
9, but not for MMP-10.  
Until the early 2000s, antibodies against MMP-3 and MMP-10 were provided by the original research 
groups and used by several other laboratories (Suppl Table 2). We found the first reports describing the 
use of commercial antibodies around the year 2004.34 However, studies directly comparing the 
specificities of antibodies against MMP-3 and MMP-10 are still extremely scarce (Suppl Table 5). 
 
 
Discussion 
MMP-3 and MMP-10 share a high degree of similarity at the amino acid level and have a similar migration 
behaviour in SDS PAGE after activation.6, 15 Because of the fact that both proteins also have overlapping 
biological functions,11 it is important to detect their expression with reliable tools that can clearly 
differentiate between both enzymes. Data postulating a distinguishable cell and/or time dependent 
expression of MMP-3 and MMP-10 are mainly based on commercial antibodies, which at least should be 
re-evaluated and verified using both proteins for comparison. A few groups addressed this problem of 
 
 
This article is protected by copyright. All rights reserved.
 potential cross-reactivity similar to our current study.17, 31 Of note, the group around Gillian Murphy24, 29 did 
intensive efforts in MMP-3 and MMP-10 research and developed peptide-derived antibodies that were 
selected from the peptide region itself and that were designed to yield specific MMP-3 or MMP-10 
antibodies. These antibodies have also been used by other groups.16, 17, 24 Unfortunately, in only one of 
the screened publications that used antibodies against MMP-3 or MMP-10 in Western blot analysis, 
immunofluorescence or immunohistochemistry, the protein specificity was clearly verified by direct 
comparison of the two proteins.17  
 
Only a few of the available commercial antibodies have actually been used in published work. For some 
of these antibodies the manufacturer state cross-reactivity, but most of them are promoted as being 
specific (Suppl Table 5). We are very well aware of the fact that it is impossible to test each and every 
available product on the market, and that the commercial antibodies we used in our study only represent 
a small fraction of all available products. Nevertheless, we demonstrate clearly that these antibodies were 
not able to discriminate clearly between MMP-3 and MMP-10 in Western blot or immunohistochemistry 
(see Figs. 1-3). Strikingly, the manufacturer declared specificity for all commercial antibodies used in our 
study in their data sheets or cross-reactivity against MMP-10 was not mentioned at all. Because the 
fixation method can have an influence on epitope recognition and activity of respective antibodies, 
different techniques for tissue fixation may cause a problem in immunohistochemistry. In our experiment, 
we fixed samples in 4% PFA throughout the experiment for identical conditions for respective analytical 
method.  
 
With regard to an analytical method that was able to differentiate between MMP-3 and MMP-10 we found 
only one exception from the previous observation. Recently, MSD® introduced ultrasensitive sandwich 
immunoassays for detection of multiple MMPs. 35 Despite of the manufacturer’s declaration of cross-
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 reactivity for both enzymes, MMP-10 was only detected by the MMP-1/-3/-9 kit at concentrations above 
10 ng/mL with no detection of MMP-3 by the MMP-2/-10 kit.  
 
Cross-reactivity between MMP-3 and MMP-10 of commercial antibodies was the initiator to address the 
specificity of the currently available products in more detail. Therefore, we developed our own peptide-
derived antibodies and selected the most diverging peptide sequences for targeted detection. Western 
blot analysis, immunofluorescence of cell lysates or immunohistochemistry of skin tissue sections showed 
how difficult it is to obtain enzyme and species specific antibodies – especially if different analytical 
methods or complex tissues are used. Out of eight selected antibodies, one anti-mouse antibody showed 
high enzyme and species specificity, the anti-human MMP-3 antibody cross-reacted with an unknown 
band at 40 kDa in Western blot analysis. When used in cell immunofluorescence or 
immunohistochemistry of paraffin embedded tissue sections, the specificity of our peptide based 
antibodies got even more distinct, with both species and enzyme specificity of the anti-mouse MMP-3 and 
both MMP-10 antibodies but cross-reactivity of the anti-human MMP-3 antibody in murine skin. One anti-
mouse and one anti-human MMP-10 antibody were specific with regard to the enzyme or species. This 
observation corresponds well with observations made by Murphy’s group with the MMP-10 antibody.31, 36 
Especially the IW13 anti-human MMP-10 is well-known for binding specifically and exclusively to human 
MMP-1031, 36 whereas some cross-reactivity with MMP-3 was found with the anti-human MMP-10 D248/6 
(Prof. Gillian Murphy, personal communication; Fig. 4). Murphy’s lab and associated groups, Dew24 and 
Bord16, commented on weak cross-reactivity with MMP-10 of the anti-mouse MMP-3 antibody L50/6 made 
by the Murphy lab.29 Clearly, it is more difficult to manufacture specific MMP-3 antibodies without 
interaction with the MMP-10 protein than vice versa. 
 
Western blot analysis yielded several bands for MMP-10 that did not correspond to the published 
molecular weight for active forms of MMP-10 at 24 kDa,37 44 kDa15 or 47 kDa.37 The lower band of MMP-
 
 
This article is protected by copyright. All rights reserved.
 10 at about 37 kDa could have resulted from amino-terminal truncation of the activated or full-length 
latent form of MMP-10 by auto-proteolytic processing or by other proteases as described previously,33 
since EDTA was not added to our extraction buffer. Nakamura et al found caseinolytic activity of 
H2NPhHgAc-activated MMP-10 at 40 kDa under non-reducing conditions.37 Similar intermediate forms 
were reported from MMP-3 after autolytic38 or APMA activation.39 MMP doublets (> 50 kDa) seen for both 
enzymes have been ascribed to glycosylation.33, 40 Anomalous migration behaviour of MMP-3 bands in 
non-reduced samples was noticed in comparison to samples run under reducing conditions.4 
In summary, MMPs are important enzymes with multiple functions in physiological and pathological 
processes. The detection of specific members of the MMP family can be challenging due to similar 
molecular weights and electrophoretic behaviour, substrate specificity, due to intracellular re-uptake or 
fast extracellular degradation. The unanimous consent of research groups within the MMP field is the 
need for a specific determination and detection of all proteinases of this group in general, and with regard 
to stromelysins, in particular. Careful attention should be paid in all investigations to check for protein 
specific binding. By using specific antibodies and by scrutinizing carefully for cross-reactivity – within the 
same experimental setting – we should gain more insight in their specific functions and distributions and, 
increase thereby the quality of our scientific results. 
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 Figure legends 
 
Fig.1 Western blot for MMP-3 of homogenized wound tissues from MMP-3 wildtype (WT) and knock-out 
(KO) mice (A) or overexpressed recombinant proteins (B) using different commercially available MMP-3 
antibodies. A. Species specificity of the anti-MMP-3 antibody M3B but cross-reactivity in MMP-3 knock-
out mouse tissue with M3D and Acris antibodies. Cross-reactivity with MMP-10 was also found in all 
samples analysed with MAB548 and JM3523. MW molecular weight marker, WT wild-type, KO MMP-3 
knock-out mouse tissue, ns normal skin, wo wound, rmMMP-3 recombinant mouse MMP-3, rhMMP-10 
recombinant human MMP-10.  
B. Western immunoblotting of cell lysates from human or mouse MMP-3 or MMP-10 overexpressing 
HepG2 cells using commercial (B) or lab-made (C) antibodies against MMP-3. Note unspecific binding of 
all commercially available anti-MMP-3 antibodies to any of the overexpressed mouse or human MMP-3 or 
MMP-10 proteins. C. Species specificity was found with the lab-made anti-mouse MMP-3 antibody L50/6 
with mild cross-reactivity against mouse MMP-10. Molecular weight markers are indicated on the left side 
of each blot. On top of blots respective overexpressed enzyme, e.g. mouse for mMMP-3 or mMMP-10 or 
human for huMMP-3 or huMMP-10.  
 
Fig. 2. Immunohistochemistry of murine excisional skin wounds from wildtype (A,C) or MMP-3 knock-out 
mice (B,D) using commercial antibodies JM3523 (A,B) and MAB 548 (C,D; see also Suppl Table 1). Note 
unspecific staining in tissue sections of both animal strains with JM3523 and positive but enzyme 
unspecific staining with the anti-MMP-3 antibody MAB 548 in both MMP-3 wildtype and MMP-3 deficient 
mouse skin wounds. Alexa green MMP-3, red DAPI. Magnification 20x, scale bar 100µm (in D for all 
samples.  
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 Fig. 3. Immunofluorescence staining of COS-7 cells overexpressing human or mouse MMP-3 or MMP-10 
with commercial antibodies M3B (Novus Biologicals, #NB110 – 57221) and M3C (Abcam, #EP1186Y). 
Note immunopositivity with M3B and M3C for human (A) and mouse (B) MMP-3 and cross-reactivity with 
human MMP-10 (C) but only weak with mouse MMP-10 (D). Magnification 40x, scale bar 50µm (for all 
samples). 
 
Fig. 4. Western blot using lab-made antibodies against MMP-3 and MMP-10, (A) sheep anti-mouse MMP-
3 antibody (L50/6), (B) sheep anti-human MMP-10 D248/6 17 or (C) sheep anti-human MMP-10 IW13 31. 
A,B. Tissue homogenates of wounds from MMP-3 wildtype and knock-out mice. rmMMP-3 (A) or MMP-10 
standard from cell lysate (c-ly; B) to the right. A. Arrow points to weak binding of MMP-3 antibody to 
activated form of MMP-10 in MMP-3 knock-out mouse tissue. B. Arrows depict position of active (44 kDa) 
and latent (54 kDa) forms of mouse tissue MMP-10 differing from position of recombinant mouse MMP-10 
from cell lysates. C. Recombinant human MMP-10 (2.5ng; left track) or tissue extract of mouse skin 
distant to a wound (right) were analysed with the IW13 anti-human MMP-10 antibody. Molecular weights 
in kDa are indicated on the left side of each blot.  
 
Fig. 5. Alignment of MMP-3 and MMP-10 from human (huMMP-3 and huMMP-10) and mouse (muMMP-3 
and muMMP-10). The amino acid sequences translated from the respective coding sequences were 
aligned using Geneious software (version 5.5) with default settings. Black frames indicate the areas with 
highest sequence diversity, which were selected for the generation of peptide antibodies prepared as 
described under methods. 
 
Fig. 6. Western immunoblotting of cell lysates from human or mouse MMP-3 or MMP-10 overexpressing 
COS-7 cells using the novel peptide antibodies against MMP-3 or MMP-10. A. Specific binding of anti-
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 mouse MMP-3 peptide 1 to recombinant mouse MMP-3. Note weak band at 105 kDa. Only weak binding 
of anti-mouse MMP-3 peptide 2 to mouse MMP-3 and cross-reactivity with recombinant human MMP-3 
and rh- and rm-MMP-10. B. Anti-human MMP-3 peptide 1 antibody bound specifically to rhMMP-3 but 
reacted also with a peptide yielding a band at 40 kDa. Unspecific binding of anti-human MMP-3 peptide 2 
antibody. C. Specific binding of anti-mouse MMP-10 peptide 1 to rmMMP-10 albeit with very weak inter-
species cross-reactivity with rhMMP-10. D. High inter-species and enzyme specificity for anti-mouse 
MMP-10 peptide 2. Anti-human MMP-10 antibodies peptide 1 was specific to enzyme and species 
whereas anti-human MMP-10 peptide 2 cross-reacted with mouse MMP-10. Molecular weights are 
indicated on the left side of each blot. mMMP-3 or MMP-10 recombinant mouse MMP, huMMP-3 or MMP-
10 human MMP. 
 
Fig. 7. Immunohistochemistry after incubation of novel peptide antibodies with strep-tagged murine or 
human MMP-3 or MMP-10 from respective enzyme overexpressing COS-7 cells. mMMP-3 mouse MMP-
3, huMMP-3 human MMP-3, mMMP-10 mouse MMP-10, huMMP-10 human MMP-10, anti huMMP-3 
peptide antibody, anti mMMP-3 peptide antibody, anti mMMP-10 peptide antibody, anti huMMP-10 
peptide antibody; analysis of antibodies with cy2 (yellow) and nuclei with DAPI (blue) filter; magnification 
40x. 
 
Fig. 8. Immunohistochemistry after incubation of novel peptide antibodies with human skin tissue. MMP-3 
and MMP-10 detection in skin after burn injury (upper row) and in non-injured normal skin (split-thickness 
skin graft, middle row 10x, lower row 40x). Anti-mouse MMP-3 (A) and MMP-10 (B) and anti-human 
MMP-3 (C) and MMP-10 (D) antibodies. E. negative control staining with secondary antibody only. 
Antigen recognition and background staining depended on type of tissue, e.g. wounded or normal tissue. 
High species specificity with no binding of anti-mouse MMP-3 (A) and weak background staining of anti-
mouse MMP-10 (B) in human skin tissues. Of note, anti-mouse MMP-10 showed more staining in burned 
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 wounds compared to normal skin. C. Distinct detection of MMP-3 by anti-human MMP-3 antibody in 
burned skin and weak staining in the basal layer of normal epidermis and dermis. D. Strong 
immunopositivity for human MMP-10 in upper layers of epidermis and dermal inflammatory cells in burned 
tissue (arrow upper row) or inside a vessel of the reticular dermis (arrows middle and lower row) with the 
anti-human MMP-10 antibody. burn, human 2nd degree burned skin wound (without epidermis), normal, 
normal human skin derived from split-thickness skin graft (0.2mm thickness) from the same donor. Scale 
bar upper and middle row 100µm (magnification 10x), scale bar lower row 50µm (40x), scale bars valid 
for all panels in the corresponding row.  
 
Fig. 9. Immunohistochemistry after incubation of novel peptide antibodies with wounded murine skin 
tissue of MMP-3 wildtype or MMP-3 knock-out mice. Anti-mouse MMP-3 (A) and MMP-10 (B) and anti-
human MMP-3 (C) and MMP-10 (D) antibodies. E. negative control staining with secondary antibody only. 
A. Specific staining for the anti-mouse MMP-3 antibody was observed with predominant antigen 
recognition the upper epidermal layers. Of note, nuclear staining of dermal inflammatory cells (arrow A). 
No immunopositivity with weak background staining was found in MMP-3 knock-out mouse tissue. B. 
Anti-mouse MMP-10 antibody showed prominent staining to the epidermis with strong nuclear staining of 
both epidermal and dermal cells of wildtype and MMP-3 knock-out skin tissue (arrows). C. Unspecific 
staining with cross-reactivity was detected with the anti-human MMP-3 antibody with prominent staining of 
the epidermis in both mouse strains. D. Weak epidermal background staining was noticed with the anti-
human MMP-10 antibody in murine tissue. E. Negative control with tissue samples stained with the 
secondary antibody only. Upper row magnification of 20x, scale bar 100µm (in E for all samples of the 
upper row), lower row 40x, scale bar 50µm (in E for all samples in the lower row). 
 
Fig. 10. Sandwich immunoassay results for the detection of MMP-1, MMP-2, MMP-3, MMP-9 and MMP-
10 assessed by the human MMP-3-Plex ultra-sensitive kit detecting human MMP-1 (A), MMP-3 (C) and 
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 MMP-9 (D) and the human MMP-2-Plex ultra-sensitive kit detecting human MMP-2 (B) and MMP-10 (E). 
Note the respective kit detects human MMPs from the pg/mL to the ng/mL range. Cross-reactivity was 
exclusively found for MMP-10 above concentrations of 10 ng/mL, which was detected as 103-fold lower 
MMP-3 concentration (arrow, E).  
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